Derazantinib
Merck
['deraza']
#basileapharmaceutica, in the poster session at 2022 conference, revealed positive results of the phase ii fides-01 study, evaluating derazantinib in patients with icca. visit to get more key insights: #esmo2022 #esmo #esmo22 #abstracts #oncology 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry